{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T01:02:16Z","timestamp":1770512536559,"version":"3.49.0"},"reference-count":36,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2015,10,7]],"date-time":"2015-10-07T00:00:00Z","timestamp":1444176000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pain Practice"],"published-print":{"date-parts":[[2016,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To compare pain medication treatment changes across cohorts of newly diagnosed patients with fibromyalgia (<jats:styled-content style=\"fixed-case\">FM<\/jats:styled-content>) treated with guideline\u2010recommended medications or opioids.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and Design<\/jats:title><jats:p>Retrospective claims data analysis examined adult commercial health plan members newly diagnosed with<jats:styled-content style=\"fixed-case\">FM<\/jats:styled-content>(initial diagnosis = index date) from January 2008 to February 2012. Patients had 6\u2010month pre\u2010index and 12\u2010month postindex periods and received pain medication within 6 months postindex; cohorts were based on the first postindex medication. Guideline\u2010recommended medication cohorts were anti\u2010epileptic drug (<jats:styled-content style=\"fixed-case\">AED<\/jats:styled-content>), serotonin\u2013norepinephrine reuptake inhibitor (<jats:styled-content style=\"fixed-case\">SNRI<\/jats:styled-content>), selective serotonin reuptake inhibitor (<jats:styled-content style=\"fixed-case\">SSRI<\/jats:styled-content>), and tricyclic antidepressant (<jats:styled-content style=\"fixed-case\">TCA<\/jats:styled-content>). Short\u2010acting and long\u2010acting opioid (<jats:styled-content style=\"fixed-case\">SAO<\/jats:styled-content>,<jats:styled-content style=\"fixed-case\">LAO<\/jats:styled-content>) cohorts were also identified. Pairwise comparisons with the<jats:styled-content style=\"fixed-case\">SAO<\/jats:styled-content>cohort were conducted. Cox proportional hazards regressions modeled the likelihood of receiving guideline\u2010recommended therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The final sample was 96,175 patients (mean age 47.3 years; 72.5% female), distributed into<jats:styled-content style=\"fixed-case\">SAO<\/jats:styled-content>(57%),<jats:styled-content style=\"fixed-case\">SSRI<\/jats:styled-content>(22%),<jats:styled-content style=\"fixed-case\">AED<\/jats:styled-content>(10%),<jats:styled-content style=\"fixed-case\">SNRI<\/jats:styled-content>(6%),<jats:styled-content style=\"fixed-case\">TCA<\/jats:styled-content>(3%), and<jats:styled-content style=\"fixed-case\">LAO<\/jats:styled-content>(2%) cohorts. The<jats:styled-content style=\"fixed-case\">SAO<\/jats:styled-content>cohort had the most discontinuation (49% vs. 6% to 22%,<jats:italic>P<\/jats:italic>&lt; 0.01) and the least augmentation (29% vs. 35% to 50%,<jats:italic>P<\/jats:italic>&lt; 0.01). Regression analyses indicated that patients with (vs. without) pre\u2010index guideline\u2010recommended medications were 2 to 4 times more likely to receive them postindex. Patients in the opioid cohorts were about half as likely to receive subsequent guideline\u2010recommended medications.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Opioid use was widespread among patients with<jats:styled-content style=\"fixed-case\">FM<\/jats:styled-content>. Once patients received opioids postdiagnosis, the likelihood of receiving guideline\u2010recommended medications was small. These real\u2010world results indicate an opportunity may exist for improved<jats:styled-content style=\"fixed-case\">FM<\/jats:styled-content>management using recommended therapies in clinical practice.<\/jats:p><\/jats:sec>","DOI":"10.1111\/papr.12364","type":"journal-article","created":{"date-parts":[[2015,10,7]],"date-time":"2015-10-07T06:18:54Z","timestamp":1444198734000},"page":"1027-1039","source":"Crossref","is-referenced-by-count":15,"title":["Evaluating Guideline\u2010recommended Pain Medication Use Among Patients with Newly Diagnosed Fibromyalgia"],"prefix":"10.1111","volume":"16","author":[{"given":"Rachel","family":"Halpern","sequence":"first","affiliation":[{"name":"Optum Eden Prairie Minnesota U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonali N.","family":"Shah","sequence":"additional","affiliation":[{"name":"Pfizer Inc New York City New York U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph C.","family":"Cappelleri","sequence":"additional","affiliation":[{"name":"Pfizer Inc Groton Connecticut U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth T.","family":"Masters","sequence":"additional","affiliation":[{"name":"Pfizer Inc New York City New York U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Clair","sequence":"additional","affiliation":[{"name":"Pfizer Inc New York City New York U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,10,7]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23176"},{"key":"e_1_2_7_3_1","doi-asserted-by":"crossref","first-page":"967","DOI":"10.47102\/annals-acadmedsg.V38N11p967","article-title":"Clinical aspects and management of fibromyalgia syndrome","volume":"38","author":"Chong YY","year":"2009","journal-title":"Ann Acad Med Singapore"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380104"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21896"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.12968\/hmed.2012.73.4.211"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2012.18.6.415"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/JOM.0b013e31815cff4b"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-9-71"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20140"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780330203"},{"key":"e_1_2_7_12_1","volume-title":"Guideline for the Management of Fibromyalgia Syndrome Pain in Adults and Children","author":"American Pain Society","year":"2005"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.4065\/mcp.2010.0738"},{"key":"e_1_2_7_14_1","unstructured":"FitzcharlesMA Ste\u2010MariePA GoldenbergDL et al.2012 Canadian guidelines for the diagnosis and management of fibromyalgia syndrome.2012.http:\/\/www.canadianpainsociety.ca\/pdf\/Fibromyalgia_Guidelines_2012.pdf(accessed October 10 2014)."},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.071522"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2012.02.010"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp100322"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1533-2500.2009.00292.x"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2011.629262"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2011.629263"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1533-2500.2010.00440.x"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1533-2500.2011.00453.x"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1533-2500.2011.00497.x"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2009.03.012"},{"key":"e_1_2_7_25_1","volume-title":"Fundamentals of Biostatistics","author":"Rosner B","year":"2010"},{"key":"e_1_2_7_26_1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables (with discussion)","volume":"34","author":"Cox DR","year":"1972","journal-title":"J R Stat Soc Series B"},{"key":"e_1_2_7_27_1","volume-title":"Survival Analysis: A Self\u2010Learning Text","author":"Kleinbaum DG","year":"2011"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/69.1.239"},{"key":"e_1_2_7_29_1","unstructured":"SAS Institute Inc.http:\/\/www.sas.com\/en_us\/home.html(accessed January 7 2015)."},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1533-2500.2011.00470.x"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/918216"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/papr.12289"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.051528"},{"key":"e_1_2_7_34_1","first-page":"898493","article-title":"Opioid use in fibromyalgia is associated with negative health related measures in a prospective cohort study","volume":"2013","author":"Fitzcharles MA","year":"2013","journal-title":"Pain Res Treat"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e3182863447"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.7556\/jaoa.2013.034"},{"key":"e_1_2_7_37_1","first-page":"1139","article-title":"Prevention, recognition, and management of serotonin syndrome","volume":"81","author":"Ables AZ","year":"2010","journal-title":"Am Fam Physician"}],"container-title":["Pain Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fpapr.12364","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/papr.12364","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T16:05:44Z","timestamp":1718121944000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/papr.12364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,7]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["10.1111\/papr.12364"],"URL":"https:\/\/doi.org\/10.1111\/papr.12364","archive":["Portico"],"relation":{},"ISSN":["1530-7085","1533-2500"],"issn-type":[{"value":"1530-7085","type":"print"},{"value":"1533-2500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,7]]}}}